Financing ·
Eupraxia Pharmaceuticals proposes to issue up to US$300M in common shares via open market sales
EPRXEupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. filed an Open Market Sale Agreement with Jefferies LLC and Jefferies Securities, Inc., dated November 10, 2026. The agreement establishes a framework for the company to sell its common shares from time to time through these agents as sales agents or principals. The maximum aggregate sales price of common shares under this program is limited to US$300 million, subject to regulatory caps and the availability of registered amounts under the company's Canadian Base Prospectus and U.S. Form F-10 registration statement. A floor price for sales will be set by the company in individual issuance notices and may not fall below US$1.00 per share. The selling commission is 3.0% of gross proceeds. Eupraxia Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.